Evidence map›Paper›PMID 28508031›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2017

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort.

Veer Bala Gupta, Eugene Hone, Steve Pedrini, James Doecke, Sid O'Bryant, Ian James, Ashley I Bush, Christopher C Rowe, Victor L Villemagne, David Ames and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Blood DNA methylation as a potential biomarker of dementia: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018
    Pooled it
  4. Trial
  5. Age-Related Cognitive Decline and Dementia: Interface of Microbiome-Immune-Neuronal Interactions.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Veer Bala GuptaSchool of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Eugene HoneSchool of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Steve PedriniSchool of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
James DoeckeCSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Queensland, Australia.
Sid O'BryantInstitute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA.
Ian JamesSchool of Engineering and Information Technology, Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Ashley I BushCo-operative Research Centre for Mental Health, Carlton, Victoria, Australia.
Christopher C RoweDepartment of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.
Victor L VillemagneThe Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.
David AmesNational Ageing Research Institute, Parkville, Victoria, Australia.
Colin L MastersThe Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.
Ralph N MartinsSchool of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
AIBL Research Group
Edith Cowan University · AUAustin Health · AUCooperative Research Centre for Mental Health · AUCSIRO Health and Biosecurity · AUMurdoch University · AUSt George Hospital · AUUniversity of Melbourne · AUUniversity of North Texas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing.

methodsWe analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort.

resultsLevels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months ( DISCUSSION: These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.

Indexed as

Alzheimer's diseaseBiomarkersBlood

Identifiers

PMID28508031
PMCPMC5423327
OpenAlexW2607110682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.